During the corresponding time, Neuraxis Inc recorded a revenue increase by 115.72 % year on year, sequentially revenue grew by 19.95 %. While revenue at the Neuraxis Inc 's corporate clients
Neuraxis Inc's Comment on Sales, Marketing and Customers
The company serves customers including children’s hospitals, adult gastroenterologists within the VA, and adult pain physicians in the VA. Its markets focus on treating functional abdominal pain related to irritable bowel syndrome (IBS), functional dyspepsia (FD), and associated FD nausea symptoms in patients aged 8 years and older. Ongoing clinical trials address pediatric and adult conditions such as post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, and fibromyalgia pain. Specific trials are conducted at Children’s Hospital of Orange County and Children’s Wisconsin/Medical College of Wisconsin, targeting pediatric patients with post-concussion syndrome and cyclic vomiting syndrome, respectively. An additional trial on post-operative pain evaluates opioid consumption reduction using the NSS-2 BRIDGE Device.
NeurAxis, Inc. (NeurAxis), a leading medical technology company specializing in neuromodulation therapies for chronic conditions, has recently made a significant breakthrough. The company has announced the successful publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) in North Dakota. This development is expected to have a significant impact on the treatment of chronic and debilitating conditions in both children and adults. NeurAxis has partnered with a Blue Cross Blue Shield (BCBS) licensee in North Dakota, which is the largest provider of health care coverage in the state, insuring and administering claims for over 310,000 individuals beginning from May 6, 20...
NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy CoverageCARMEL, Ind., March 04, 2024 - NeurAxis, Inc. (NeurAxis), a leading medical technology company specializing in the commercialization of neuromodulation therapies for chronic and debilitating conditions in children and adults, is pleased to announce that it has secured policy coverage from Blue Cross and Blue Shield of Kansas City (BCBSKC). This coverage will extend to approximately one million lives, providing access to much-needed treatment options in the Kansas City, Missouri metropolitan areas, including Johnson and Wyandotte counties in Kansas.The partnership between NeurAxis and BCBSKC marks a significant milestone in expanding ...
Neuraxis Inc’s Comment on Sales, Marketing and Customers
The company serves customers including children’s hospitals, adult gastroenterologists within the VA, and adult pain physicians in the VA. Its markets focus on treating functional abdominal pain related to irritable bowel syndrome (IBS), functional dyspepsia (FD), and associated FD nausea symptoms in patients aged 8 years and older. Ongoing clinical trials address pediatric and adult conditions such as post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, and fibromyalgia pain. Specific trials are conducted at Children’s Hospital of Orange County and Children’s Wisconsin/Medical College of Wisconsin, targeting pediatric patients with post-concussion syndrome and cyclic vomiting syndrome, respectively. An additional trial on post-operative pain evaluates opioid consumption reduction using the NSS-2 BRIDGE Device.
Sources:
Neuraxis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Neuraxis Inc’s corporate clients.
For your research, we’ve provided 9 tables on Neuraxis Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
